@article{4ac01e36dfca419fb1b2591aa511cd71,
title = "Clinically Actionable Strategies for Studying Neural Influences in Cancer",
abstract = "Neuro-glial activation is a recently identified hallmark of growing cancers. Targeting tumor hyperinnervation in preclinical and small clinical trials has yielded promising antitumor effects, highlighting the need of systematic analysis of neural influences in cancer (NIC). Here, we outline the strategies translating these findings from bench to the clinic.",
author = "Demir, {Ihsan Ekin} and Reyes, {Carmen Mota} and Wasfi Alrawashdeh and Ceyhan, {G{\"u}ralp O.} and Sylvie Deborde and Helmut Friess and Kivanc G{\"o}rg{\"u}l{\"u} and Rouzanna Istvanffy and David Jungwirth and Rohini Kuner and Maria Maryanovich and Shorook Na'ara and Simon Renders and Saloman, {Jami L.} and Scheff, {Nicole N.} and Hendrik Steenfadt and Pavel Stupakov and Vera Thiel and Divij Verma and Yilmaz, {Bengi Su} and White, {Ruth A.} and Wang, {Timothy C.} and Wong, {Richard J.} and Frenette, {Paul S.} and Ziv Gil and Davis, {Brian M.}",
note = "Funding Information: The consensus recommendations in this Commentary have been gathered during the 1 st Neural Influences in Cancer (NIC) International Think Tank Meeting, which took place November 7–9, 2019 in Heidelberg, Germany. I.E.D. was awarded with the ENIGMA Young Investigator Prize of the Society for Scientific Meetings in Biomedicine to organize the NIC meeting. We thank Society for Scientific Meetings in Biomedicine (Verein f{\"u}r wissenschaftliche Fachtagungen in der Biomedizin e.V. / VWFB e.v) and its Chair Hellmut Augustin for support. The meeting was also supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft/DFG DE2428/7-1 ) and the Fritz Thyssen Foundation ( 30.19.0.128MN ). R.K. is a member of the Molecular Medicine Partnership Unit of Medical Faculty Heidelberg and the European Molecular Biology Laboratory and is supported by a grant from the Visionary Novel Concepts in Cancer Research program . M.M. is a New York Stem Cell Foundation (NYSCF) Druckenmiller fellow and was supported by the EMBO European Commission FP7 (Marie Curie Actions; EMBOCOFUND2012 , GA-2012-600394 , ALTF 447-2014 ). T.C.W. is a Consultant for Novo Nordisc and Glaxo SmithKline and on the Scientific Advisory Board for Cygnal Therapeutics. The remaining authors report no financial disclosures or no conflicts of interest. Funding Information: The consensus recommendations in this Commentary have been gathered during the 1st Neural Influences in Cancer (NIC) International Think Tank Meeting, which took place November 7–9, 2019 in Heidelberg, Germany. I.E.D. was awarded with the ENIGMA Young Investigator Prize of the Society for Scientific Meetings in Biomedicine to organize the NIC meeting. We thank Society for Scientific Meetings in Biomedicine (Verein f{\"u}r wissenschaftliche Fachtagungen in der Biomedizin e.V. / VWFB e.v) and its Chair Hellmut Augustin for support. The meeting was also supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft/DFG DE2428/7-1) and the Fritz Thyssen Foundation (30.19.0.128MN). R.K. is a member of the Molecular Medicine Partnership Unit of Medical Faculty Heidelberg and the European Molecular Biology Laboratory and is supported by a grant from the Visionary Novel Concepts in Cancer Research program. M.M. is a New York Stem Cell Foundation (NYSCF) Druckenmiller fellow and was supported by the EMBO European Commission FP7 (Marie Curie Actions; EMBOCOFUND2012, GA-2012-600394, ALTF 447-2014). T.C.W. is a Consultant for Novo Nordisc and Glaxo SmithKline and on the Scientific Advisory Board for Cygnal Therapeutics. The remaining authors report no financial disclosures or no conflicts of interest. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = jul,
day = "13",
doi = "10.1016/j.ccell.2020.05.023",
language = "English (US)",
volume = "38",
pages = "11--14",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",
}
